Ibogaine is not scheduled under Argentine federal law, placing it in a legal gray zone where possession and use are neither explicitly authorized nor criminalized. Last verified: April 22, 2026.

Current Legal Status

Argentina regulates controlled substances primarily through Law 23.737 (Narcotic Drugs and Psychotropic Substances Act, 1989) and its implementing decrees, which adopt lists closely mirroring the UN Convention on Psychotropic Substances schedules. Ibogaine and its primary alkaloid source, Tabernanthe iboga, do not appear on any of Argentina's national scheduling lists. The Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT) — Argentina's equivalent of a drug regulatory agency — has not approved ibogaine as a pharmaceutical product, nor has it classified it as a prohibited substance.

This omission means:

  • Simple possession is not a criminal offense under current federal statute.
  • There is no explicit license framework authorizing commercial sale or medical prescription.
  • Provincial authorities retain some discretion over health regulation, and local enforcement can vary.
  • No religious exemption framework exists specifically for ibogaine, unlike some countries that recognize plant-medicine ceremonies under indigenous or religious-freedom protections.
Important: "Unscheduled" does not mean "legal" in a comprehensive sense. ANMAT can take administrative action against unauthorized pharmaceutical products. The gray-zone status creates practical risk even without a criminal statute directly targeting ibogaine.

Treatment Centers

A small number of clinics and retreat operators in Argentina offer ibogaine-assisted sessions, primarily concentrated in Buenos Aires and surrounding provinces. Because ibogaine is unscheduled rather than expressly authorized as a medicine, these operations typically function under general health-provider or wellness-retreat licensing rather than a specific ibogaine clinic permit. Medical supervision varies significantly between providers.

For a curated, regularly updated directory of Argentina-based ibogaine providers, including screening criteria and safety profiles, visit our full clinic directory.

How People Access Ibogaine in Argentina

The following reflects observed access patterns and is reported factually without endorsement or recommendation:

  • Private clinics and retreat centers: The most common route. Several facilities advertise ibogaine treatment openly, often targeting both Argentine residents and international medical tourists from neighboring countries or from regions where ibogaine is more strictly controlled.
  • Underground or informal networks: Some individuals access ibogaine through informal channels outside any clinical setting, accepting substantially higher personal risk.
  • Medical tourism inbound: Argentina's relatively low cost of living compared to Western Europe and North America, combined with the unscheduled status, attracts international visitors seeking treatment unavailable at home.
  • Harm-reduction organizations: A growing network of psychedelic harm-reduction groups in Buenos Aires provides information and referrals, though they do not administer substances themselves.

Recent Legal Developments

Argentina has experienced notable movement in its broader psychedelic policy landscape over the past two years:

  • Psilocybin and MDMA research authorization (2024–2025): ANMAT approved limited clinical research protocols for psilocybin-assisted psychotherapy and MDMA-assisted therapy, signaling regulatory openness to psychedelic-assisted treatments without scheduling the compounds outright. This precedent is frequently cited by ibogaine advocates as a potential pathway for future formal authorization.
  • Congressional proposals: At least two draft bills circulated in the Argentine Chamber of Deputies during 2024–2025 that would create a formal regulatory framework for psychedelic-assisted psychotherapy, including ibogaine. Neither has advanced to a full floor vote as of April 2026.
  • Harm reduction legislation: Amendments to Law 23.737 proposed in 2025 would shift enforcement emphasis further toward treatment and harm reduction over criminalization, which advocates argue could indirectly benefit ibogaine's regulatory trajectory.
  • No adverse enforcement actions: No publicly reported federal prosecutions specifically targeting ibogaine possession or administration have been identified in the past two years.

Risks of Seeking Treatment in Argentina

While Argentina's unscheduled status reduces legal exposure compared to many countries, significant risks remain:

  • No standardized clinical protocols: Without a formal approval pathway, there is no mandated protocol for cardiac screening, dosing, or emergency response. Quality and safety standards vary enormously between providers.
  • Cardiac risk: Ibogaine is associated with QT-interval prolongation and cardiac arrhythmia. Reputable providers require a pre-treatment electrocardiogram (ECG) and full cardiac workup, but this is not legally required in Argentina and not universally practiced.
  • Drug interaction hazards: Ibogaine has dangerous interactions with opioids, certain antidepressants, and other substances. Without standardized intake procedures, contraindicated medications may not be identified.
  • Lack of legal recourse: Because ibogaine treatment operates outside a formal medical licensing framework, patients have limited recourse through Argentine medical malpractice law if something goes wrong.
  • Provincial variability: While no province currently schedules ibogaine, local health authorities could theoretically take administrative action against a specific provider, creating operational instability.
  • International travel considerations: Travelers returning home from Argentine ibogaine treatment should be aware that their home country may still criminalize the substance, and that carrying any residual ibogaine across borders constitutes a separate legal risk.

Frequently Asked Questions

Ibogaine is not listed on any of Argentina's federal controlled substance schedules under Law 23.737 or related decrees, making it technically unscheduled. It is neither expressly legal (ANMAT has not approved it as a medicine) nor expressly illegal (no criminal statute targets it). This gray-zone status has persisted without significant legal challenge, but it is not equivalent to a formal legal authorization.
Argentina does not restrict entry for the purpose of seeking wellness or medical treatments, and the unscheduled status of ibogaine means there is no Argentine law specifically criminalizing a foreign national's participation in ibogaine therapy on Argentine soil. However, travelers must consider the laws of their home country — particularly whether returning home after ibogaine treatment could create legal exposure — and the health risks associated with international travel immediately following treatment. Consult a licensed attorney in both your home country and Argentina before proceeding.
Medical supervision is not legally mandated for ibogaine providers in Argentina because no specific regulatory framework exists. Some facilities operate with licensed physicians, psychiatrists, and cardiac monitoring equipment; others do not. Due diligence — including verifying provider credentials, requesting evidence of pre-treatment cardiac screening protocols, and confirming emergency response capabilities — is essential for anyone considering treatment. Our clinic directory includes safety criteria for listed providers.
Yes, in either direction. ANMAT has the administrative authority to add substances to controlled schedules without requiring a full act of Congress. Conversely, pending legislative proposals could create a formal authorization pathway. The current political environment in Argentina appears more interested in regulated access than in restriction, but regulatory status can shift quickly. Monitor official ANMAT publications and legislative tracking services for updates.
No. Because ANMAT has not approved ibogaine as a pharmaceutical treatment, neither the public health system (PAMI, obras sociales) nor private health insurers (prepagas) cover ibogaine therapy. Patients bear the full out-of-pocket cost. Prices at Argentine clinics are generally lower than equivalent services in Western Europe or North America, but costs still vary significantly by provider and treatment protocol.
Argentina does not have a formal religious or indigenous exemption framework for ibogaine comparable to Brazil's recognized use of ayahuasca through the União do Vegetal and Santo Daime churches. The Bwiti tradition — the primary ceremonial context for ibogaine — is not indigenous to Argentina and has no established legal recognition under Argentine law. Some ayahuasca ceremonies operate under informal religious-freedom arguments in Argentina, but this precedent has not been formally extended to ibogaine.

Informational only. Not legal advice. Laws change. Verify with a licensed attorney before making any decisions.